D013844Chemicals & DrugsD02.886.675D03.383.129.708681310.925761Thiazolesprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonMedicine-Infectious Diseases32304242Bossone KA, Ellis JA, Holaska JMMuscle & nerveHistone acetyltransferase inhibition rescues differentiation of emerin-deficient myogenic progenitors. Muscle Nerve. 2020 07; 62(1):128-136.Muscle Nerve2020-05-06T00:00:002020Histone acetyltransferase inhibition rescues differentiation of emerin-deficient myogenic progenitors.30508794Islam MS, Ghawas HM, El-Senduny FF, Al-Majid AM, Elshaier YAMM, Badria FA, Barakat ABioorganic chemistrySynthesis of new thiazolo-pyrrolidine-(spirooxindole) tethered to 3-acylindole as anticancer agents. Bioorg Chem. 2019 02; 82:423-430.Bioorg Chem2018-10-23T00:00:002018Synthesis of new thiazolo-pyrrolidine-(spirooxindole) tethered to 3-acylindole as anticancer agents.34285133Drayman N, DeMarco JK, Jones KA, Azizi SA, Froggatt HM, Tan K, Maltseva NI, Chen S, Nicolaescu V, Dvorkin S, Furlong K, Kathayat RS, Firpo MR, Mastrodomenico V, Bruce EA, Schmidt MM, Jedrzejczak R, Muñoz-Alía MÁ, Schuster B, Nair V, Han KY, O'Brien A, Tomatsidou A, Meyer B, Vignuzzi M, Missiakas D, Botten JW, Brooke CB, Lee H, Baker SC, Mounce BC, Heaton NS, Severson WE, Palmer KE, Dickinson BC, Joachimiak A, Randall G, Tay SScience (New York, N.Y.)Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science. 2021 08 20; 373(6557):931-936.Science2021-07-20T00:00:002021Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2.3.08730.0080304968research area of0.8299770.0215453114subject area forMedicinePathologyUniversity of ChicagoGeorgeBakris0GBoa7McCszMknJtY0fp/Cv/+94=George Bakris41.78927490000000-87.601250000000001393Bakris, GeorgeProfessorMichaelBeckerMichael A. Becker41.78927490000000-87.601250000000001603Becker, MichaelEmeritus/Emerita, ProfessorStephen C.MeredithStephen C. Meredith41.78927490000000-87.601250000000002188Meredith, Stephen C.ProfessorJamesHolaskaJames Holaska41.78927490000000-87.60125000000000634Holaska, JamesAssistant ProfessorKathleenMullaneKathleen Mullane41.78927490000000-87.60125000000000635Mullane, KathleenClinical Professortrue1Assistant ProfessorAssistant Professortrue1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1ProfessorProfessortrue1Clinical ProfessorClinical Professortrue1ProfessorProfessor26084805Fu S, Yalcin A, Lee GY, Li P, Fan J, Arruda AP, Pers BM, Yilmaz M, Eguchi K, Hotamisligil GSScience translational medicinePhenotypic assays identify azoramide as a small-molecule modulator of the unfolded protein response with antidiabetic activity. Sci Transl Med. 2015 Jun 17; 7(292):292ra98.Sci Transl Med2015-06-17T00:00:002015Phenotypic assays identify azoramide as a small-molecule modulator of the unfolded protein response with antidiabetic activity.Medicine-Endocrinology26234174Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HMThe Lancet. OncologyVosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-1036.Lancet Oncol2015-07-30T00:00:002015Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.